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Background: Previous studies have suggested that zinc is involved in insulin homeostasis. Adiponectin is a well-
known adipokine with anti-diabetic, anti-atherogenic, and anti-inflammatory properties. The aim of this study
was to investigate the effect of zinc supplementation on glycemic control, and the potential mediating role of
adiponectin, in patients with type 2 diabetes.
Methods: In this randomized double-blind placebo-controlled clinical trial, 60 patients with diabetes, 30-60
years, were randomized to receive either 30mg/d zinc (as zinc gluconate) or placebo for 12 weeks. Circulating
levels of adiponectin, zinc, glucose homeostasis parameters, and lipid profiles, as well as anthropometric
parameters and dietary intakes, were assessed.
Results: About 53.3% of the patients had zinc insufficiency at baseline. Serum zinc levels improved significantly
in the intervention than control group following 12 weeks supplementation (P < 0.001). Adiponectin
(1.23 ± 2.23 μg/ml, P= 0.006) and insulin (3.6 ± 4.66 μIU/ml, P= 0.001) levels increased significantly
compared to baseline in the zinc group; but this change was not significant compared with the control group.
Following supplementation, there were no significant differences in glycemic control and anthropometric
parameters between the two groups. Serum HDL levels increased significantly in the zinc (5.37 ± 14.8mg/dl)
compared to control (-1.53 ± 6.9mg/dl) group following supplementation (P= 0.039).
Conclusion: Despite a significant increase in serum zinc level, no improvement was observed in glycemic control,
following 12 weeks supplementation with 30mg/d zinc (as zinc gluconate). Zinc supplementation restored
adiponectin concentrations partly within the intervention group, and increased HDL levels compared to the
control group. The current findings did not support improvement in glucose homeostasis following zinc sup-
plementation in patients with type 2 diabetes under the present study design.
1. Introduction
The prevalence of diabetes has increased worldwide in recent dec-
ades predominantly due to obesity, unhealthy lifestyle and eating pat-
terns [1]. Diabetes induces various disorders including cardiovascular
disease and stroke, non-traumatic amputations, advanced organ fail-
ures, and neuropathies, which cause high mortality, morbidities and
financial burden to health systems [2]. Available medications were
developed to manage metabolic disorders and improve quality of life in
diabetes. However, as they were not fully able to control diabetes as-
sociated complications, the potential benefits of complementary
therapies have been considered progressively.
Zinc is one of the essential trace elements for human that exists in
more than 300 metalloenzymes and 2500 translation factors and par-
ticipates ubiquitously in many cellular functions and metabolic path-
ways involved in growth, immunity, reproduction, and neurological
development [3]. It has been suggested that zinc is essential for the
synthesis of insulin, the function of its receptors and associated kinases,
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and translocation of glucose transporter 4 (GLUT4) [4,5]. The mem-
brane zinc transporter ZnT8 gene variants, which transports zinc to the
secretory insulin and glucagon granules of pancreatic islet β and α cells,
may be also correlated with diabetes risk [6,7]. The effects of zinc on
glucose homeostasis is partly due to activating the insulin-signaling
cascade via the phosphoinositide 3-kinase (PI3K) and protein kinase B
(Akt) pathways [8]. Additionally, zinc has an important role in the
regulation of the transcription factor peroxisome proliferator activated
receptor-γ (PPARγ) activity signaling [9]. PPARγ activation could im-
prove insulin sensitivity and dyslipidemia that may be mediated, at
least in part, by up-regulating adipose-derived insulin-sensitizing hor-
mones like adiponectin [10].
Adiponectin is a well-recognized adipokine considering its anti-
atherogenic, anti-inflammatory and anti-diabetic properties [11]. Thus,
it has been considered as a novel therapeutic target in metabolic dis-
orders. The effect of supplementation with zinc has been assessed in the
regulation of glucose and insulin homeostasis. However, studies did not
show conclusive results about the efficacy of this vital nutrient on
glycemic control [12,13]. Besides, the probable role of adiponectin in
mediating the effects of zinc on glycemic control has not been well
studied in clinical studies so far. Experimental models have shown that
daily oral administration of zinc compounds could improve glycemic
control and restore suppressed levels of adiponectin in obesity-linked
type 2 diabetic mice [14] and high-fat diet-fed streptozotocin induced
diabetic rats [15]. Thus, the aim of this study was to investigate the role
of zinc supplementation on glycemic control and lipid profile of pa-
tients with type 2 diabetes and the potential mediating role of adipo-
nectin in this regard.
2. Material and methods
2.1. Participants
Patients with diabetes, age 30-60 years, and stable medication
protocol within the past three months were recruited to the study from
a diabetes management center affiliated to the Kashan University of
Medical Sciences.
Non-inclusion criteria included pregnant, lactating and post-meno-
pausal women, treatment with insulin, smoking, patients with history
of acute or chronic renal failure, cardiovascular diseases, thyroid dys-
function, gastrointestinal and liver diseases, cancer, recent surgery and
acute infections, people receiving trace element supplements in the
previous three months, or medications that could affect body weight or
interfere with zinc metabolism such as oral contraceptives, anti-de-
pressants and anti-psychotics, hormones, glucocorticoids, diuretics and
antibiotics. The sample size was determined based on adiponectin le-
vels as the primary outcome. Considering a power of 80% to detect 2
unit change in adiponectin, a type I error of 0.05, and a drop-out rate of
˜10%, the sample size of 32 participants in each group was calculated.
The study protocol was approved by the Ethics committee of the Tehran
University of Medical Sciences and was conducted according to the
Declaration of Helsinki. Patients were aware of the study purposes and
signed an informed consent form.
2.2. Study design
In this randomized, double-blind, placebo-controlled, parallel-de-
sign trial, participants were randomly allocated to intervention and
control groups using block randomization procedure of size 4. The
random sequence was generated using random allocation software by
the study statistician and assigning the participants to two groups was
conducted by an independent person. Patients in the intervention group
received a daily dose of 30mg zinc as zinc gluconate (Nature Made
Nutritional Products, Mission Hills, CA, USA) and the control group
received identical-appearing placebo (manufactured by the Institute of
Pharmaceutical Sciences, Tehran University of Medical Sciences,
Tehran, Iran) for 12 weeks. The medication boxes were labeled as A and
B and the researchers and participants were blinded to the allocation.
All participants were instructed to continue their usual dietary habits
and physical activity during the study. Patients were excluded if they
did not consume more than 10% of the supplements. They were fol-
lowed up every two weeks to check the compliance and probable side
effects.
2.3. Biochemical analysis
Venous blood samples (10 cc) were collected after an overnight fast
and centrifuged at 3500 rpm for 10min. The plasma and serum frac-
tions were stored at -80ºc until analyses were performed. Determination
of serum zinc concentration was performed by atomic absorption
spectrophotometry (Shimadzu, AA680 G, Japan). Serum adiponectin
concentrations were determined using an enzyme-linked im-
munosorbent assay (ELISA) kit (Adipogen Inc., Seoul, Korea). Serum
fasting blood glucose (FBG) concentration was determined by glucose
oxidase enzymatic method (Pars Azmoon Inc., Iran) and plasma HbA1c
measured using ion-exchange high pressure liquid chromatography
(HPLC) method (Bio Systems SA, Barcelona, Spain). Serum lipid pro-
files, total cholesterol, triglyceride (TG), low density lipoprotein (LDL),
and high density lipoprotein (HDL) were measured using standard
biochemical methods (Pars Azmoon Inc., Iran). Serum insulin level was
assessed using an immunoradiometric method (Biosource Europe SA,
Belgium). Insulin resistance (IR) was calculated by the homeostasis
model assessment for insulin resistance (HOMA-IR) model as fasting
insulin (μU/ml) × fasting glucose (mmol/L) / 22.5.
2.4. Anthropometries and dietary intake
Anthropometric parameters including body weight, height, and
waist circumference (WC) were measured using standard techniques,
with light clothing and barefoot, at baseline and following 12 weeks
intervention. Body mass index (BMI) was calculated by dividing weight
(kg) by squared height (m2). At the beginning and end of the study, a
three-day 24-h dietary recall was obtained from all participants by a
trained dietitian. Dietary data were analyzed by Nutritionist IV soft-
ware (N Squared Computing, San Bruno, CA, USA) modified for local
foods.
2.5. Statistical analysis
All statistical tests were performed using SPSS18 software (SPSS
Inc., IL, Chicago, USA). Kolmogorov–Smirnov test was used to de-
termine normality of the variables. Comparisons of baseline char-
acteristics were performed using Student’s t-tests (for normal variables)
and Mann-Whitney test (for non-parametric variables). Paired t-test and
Wilcoxon singed rank test were applied for within group comparisons
(after supplementation compared to baseline). The effect of the inter-
vention was investigated by ANCOVA test adjusting for baseline values
and other potential confounders. P < 0.05 was considered to be sta-
tistically significant.
3. Results
3.1. General characteristics
Among 64 patients who were included, 60 (30 in each group)
completed the study. In each study group, 2 patients were reluctant to
finish the study due to personal reasons (Fig. 1).
There were no significant differences in sex, age, type of hypogly-
cemic medications, hypertension, and duration of diabetes between two
groups at baseline (Table 1). The mean reported dietary intakes de-
monstrated no significant differences in reported calorie, macro-nu-
trients, and zinc intakes between two groups at the beginning of the
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study (Table 1). There was not also any difference in dietary intakes
between the study groups at the end of the trial.
3.2. Serum adiponectin and zinc concentration
Our results showed that serum zinc levels were below the cut-off of
70 μg/dl in %53.3 of the participants (50% of the zinc and 56.7% of the
control group). There was no significant difference in serum zinc value
between two groups at baseline. Following 12 weeks supplementation,
serum zinc levels were significantly higher in zinc than the control
group (43.88 ± 18.55 vs. 2.55 ± 7.71 μg/dl, P < 0.001). The circu-
lating levels of adiponectin increased significantly throughout the
study, (1.23 ± 2.23 μg/ml change from baseline, P=0.006) in the
zinc group; but the difference was not statistically significant compared
with the control group following the supplementation (Table 2).
3.3. Glycemic control and lipid profile
HbA1c decreased marginally (-0.48 ± 1.33 % changes from base-
line, P=0.059) following supplementation; however, this decrease did
not attain statistical significance and was not considerably different
compared to the control group at the end of the study. Changes in
fasting blood glucose were not statistically significant between the zinc
and control groups. After the intervention, fasting insulin increased
significantly in the zinc group (3.6 ± 4.66 μIU/ml compared to base-
line, P=0.001), but this change was not statistically different from the
control group. HOMA-IR values increased at the end of the study in
both the zinc (P=0.003) and control (P= 0.021) groups compared to
baseline. There was no significant difference in HOMA-IR between the
two groups following the intervention (Table 3).
The findings showed a significant increase in serum concentrations
of HDL in the intervention compared to the control group (5.37 ± 14.8
vs. -1.53 ± 6.9mg/dl, P= 0.039). No other changes were observed in
TG, cholesterol, and LDL levels following supplementation.
3.4. Anthropometric parameters
At baseline there were no statistically differences in weight
(73.2 ± 9.5 vs. 72.2 ± 8.9 kg, P=0.676), BMI (26.96 ± 2.9 vs.
26.9 ± 2.74 kg/m², P=0.894), and WC (97.6 ± 8 vs.
95.5 ± 6.9 cm, P=0.263) between the zinc and control groups, re-
spectively. No significant differences were also seen in weight
(P= 0.584), BMI (P=0.695), or WC (P=0.879), at the end of the
study. Additionally, following supplementation, there were not sig-
nificant differences in changes of weight (-0.4 ± 2.13 vs.
-0.63 ± 1.7 kg, P=0.641), BMI (-0.16 ± 0.8 vs. -0.22 ± 0.59 kg/
m², P= 0.718), and WC (-1.12 ± 3.88 vs. -0.68 ± 3.08 cm,
P= 0.634) between the zinc and control groups, respectively.
4. Discussion
The current study showed that following 12 weeks supplementation
with 30mg/d zinc in patients with diabetes, circulating adiponectin
increased remarkably in the intervention group compared to baseline,
which was not albeit significantly different from the control group at
the end of the study. There was no significant improvement in glycemic
control following supplementation with zinc. Zinc concentration in-
creased considerably in the zinc compared to the control group fol-
lowing the study termination.
Fig. 1. CONSORT flow diagram of the study population.
Table 1
Baseline characteristics of the study population.
Group P
Control (n=30) Zinc (n=30)
Age, years (Mean±SD) 45.5± 5.4 46.2±5.3 0.613†
Male, n (%) 15 (50) 17 (56.7) 0.796*
Diabetes duration, years
(Mean±SD)
9±4.1 7.1± 3.5 0.065†
Drugs, n
(%)
Metformin 2 (6.7) 6 (20.7) 0.356*
Glibenclamide 6 (20) 5 (17.2)
Both 22 (73.3) 18 (62.1)
Hypertension, n (%) 8 (26.7) 10 (33.3) 0.779*
Dietary intake (Mean±SD)
Energy (kcal/d) 1217.4± 237.3 1362.6± 325 0.053†
Carbohydrate (g/
day)
161.4±44.4 184.8± 58.5 0.087†
Protein (g/day) 44.5± 13.4 50.2±13 0.096†
Fat (g/day) 47.5± 10.5 51.2±11.3 0.203†
Zinc (mg/day) 6.6± 2.3 7.5± 2 0.125†
† Based on t-test.
* Based on Chi-Square test.
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The initial serum zinc concentrations were below the reference
values (70 μg/dl) in nearly 50% of the patients of both groups. Many
studies have reported decreased zinc concentration and increased ur-
inary zinc excretion in patients with diabetes [16]. Despite the presence
of only about 1% of the total body zinc in circulation, both plasma and
serum zinc levels are considered valid biomarkers of zinc status [3]. In
the current study, we used zinc gluconate for supplementation. The
most common forms of zinc compounds are zinc sulfate, zinc gluconate,
zinc acetate, and zinc oxide. Zinc sulfate and zinc gluconate were
mentioned most frequently in previous studies. The published data has
indicated high and comparable absorption of zinc gluconate, zinc ci-
trate, and zinc sulfate, while zinc oxide is slightly less absorbed. Be-
sides, zinc gluconate has better sensory properties and is odorless
compared with zinc sulfate and zinc acetate that have strong metallic
and bitter taste, which needs to be covered in supplements [17]. Sup-
plementation with 30mg zinc improved zinc deficiency significantly in
the intervention group. However, there were no significant differences
in HbA1c, FBG, insulin, and HOMA-IR between the two groups fol-
lowing 12 weeks supplementation with 30mg zinc in this trial. Fasting
insulin increased significantly compared to baseline in the zinc group.
HOMA-IR changed considerably compared to the initial values in both
groups.
Despite the suggested mechanisms involved in the relationship be-
tween zinc and glucose homeostasis, many clinical trials failed to show
any advantageous effect in improving glycemic control in patients with
diabetes following supplementation with 100mg zinc sulfate for 12
weeks [18], 50mg zinc gluconate for 4 weeks [19], or 40mg elemental
zinc for 12 weeks [20]. A meta-analysis showed a considerable reduc-
tion in FBG and postprandial blood glucose and no significant change in
HbA1c. Insulin concentration and insulin resistance were not assessed
in this meta-analysis and primary studies had a high heterogeneity
[13]. In this trial, HbA1c decrease was marginally significant compared
to baseline in the zinc group. Multiple studies have also shown a sig-
nificant decrease in HbA1c only within the intervention groups com-
pared to baseline, which did not statistically differ from the control
groups following zinc supplementation [21–24]. Different supple-
mentation protocols including 22mg zinc as zinc sulfate for 4 months
[22], 30mg zinc as zinc sulfate for 3 months [21,23], and 660mg zinc
sulfate for 6 weeks [24] have been used in these studies. Similarly,
positive changes in FBG and postprandial blood glucose (22mg zinc as
zinc sulfate for 4 months) [22], and serum levels of insulin and HOMA-
IR (30mg zinc aminochelate for 4 weeks) [25] in other studies were
confined to post- vs. pre-values in the intervention groups, and were not
different from the placebo groups at the end of trials. Thus, the accu-
racy of positive reported results in some previous studies needs to be
reviewed to avoid biases and misinterpretations.
Insulin levels increased remarkably in the zinc group compared to
baseline. This change was not accompanied with improvement in gly-
cemic control. An experimental study in diabetes-prone BB Wistar rats
showed that animals fed a diet containing 1000 ppm zinc, had higher
serum and pancreatic insulin levels and lower serum glucose than those
fed low zinc diets [26]. Zinc has also improved β cell function in pa-
tients with pre-diabetes [27]. Another clinical study did not confirm
these findings; however, this trial has been done in healthy adolescence
receiving low doses of zinc (9mg zinc as zinc sulfate) for 4 weeks [28].
HOMA-IR did not differ between groups at the end of this study; al-
though it has been elevated in both groups compared to baseline. This
observation could not be completely justified in the current study as
Table 2
Changes in adiponectin and zinc serum levels throughout the study.
Control (n=30) Zinc (n=30) Diff 95% CI P
Mean± SD Mean±SD Lower Upper
Adiponectin (μg/ml) Before 8.96±4.47 7.66± 3.18 1.3 −0.704 3.304 0.115‡
After 9.32±3.45 8.89± 3.21 0.470 −0.576 1.516 0.372§
Change 0.36±2.39 1.23± 2.23 −0.87 −2.064 0.324 0.359‡
P₤ 0.269 0.006
Zinc (μg/dl) Before 71.02± 24.56 70.68±19.05 0.333 −11.027 11.693 0.442‡
After 73.57± 20.84 114.57± 18.22 −41.229 −47.715 −34.743 <0.001§
Change 2.55±7.71 43.88±18.55 −41.333 −48.674 −33.993 <0.001‡
P₤ 0.012 < 0.001
‡Based on Mann-Whitney test.
₤Based on Wilcoxon singed rank test.
§Adjusted for baseline values based on ANCOVA.
Table 3
Changes in glucose homeostasis parameters and lipid profile throughout the
study.
Control (n=30) Zinc (n=30) P
Mean± SD Mean± SD
HbA1c (%) Before 9± 1.7 8.9± 1.7 0.704†
After 8.6±1.6 8.4± 1.3 0.58§
Change −0.4± 1.22 −0.48± 1.33 0.81†
P¥ 0.088 0.059
Fasting Blood Glucose
(mg/dl)
Before 179.7± 45.6 156.9± 46.9 0.064†
After 183± 57.6 152.1± 45.2 0.201§
Change 3.34± 31.75 −4.8± 41.03 0.398†
P¥ 0.575 0.527
Insulin (μIU/ml) Before 8.6± 5 8.01± 4.5 0.84‡
After 10± 3.9 11.7± 6.3 0.068§
Change 1.36±4.31 3.6± 4.66 0.131‡
P₤ 0.074 0.001
HOMA-IR Before 3.6± 2 3.2± 2.2 0.375‡
After 4.5±2.2 4.4± 3.2 0.811§
Change 0.89±2.21 1.15± 2.46 0.913‡
P₤ 0.021 0.003
Triglyceride (mg/dl) Before 174.6± 79.2 187.5± 97.9 0.574‡
After 156.3± 57.1 170.4± 76.4 0.567§
Change −18.3± 58 −17.2± 74.8 0.723‡
P₤ 0.139 0.622
HDL (mg/dl) Before 33.2± 7.6 30.3± 6.39 0.064‡
After 31.7± 7.4 35.6± 14.5 0.071§
Change −1.53± 6.9 5.37± 14.8 0.039‡
P₤ 0.302 0.067
LDL (mg/dl) Before 103.4± 24.5 97.8± 22.8 0.206‡
After 100.4±26 96.9± 35.3 0.862§
Change −3±23.4 −0.93± 25.2 0.446‡
P₤ 0.504 0.719
Cholesterol (mg/dl) Before 181.6± 40.1 174.5± 37.19 0.183‡
After 173.4± 46.3 171.67± 47.98 0.733§
Change −8.13± 45.12 −2.83±32.17 0.308‡
P₤ 0.099 0.627
† Based on t-test.
‡ Based on Mann-Whitney test.
¥ Based on Paired Samples Test.
₤ Based on Wilcoxon singed rank test.
§ Adjusted for baseline values based on ANCOVA.
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diabetes is a complex and multifactorial disease, with different factors
that affect its management and progression. The simultaneous increase
in HOMA-IR in both the intervention and control groups indicates the
involvement of unknown variables other than zinc supplement in ex-
acerbating insulin resistance. Interestingly, few studies have reported
changes in insulin resistance following zinc supplementation in dia-
betes and the available meta-analysis did not mention this important
clinical outcome. The reference values of insulin are considered 2-25
μIU/ml [29]. In this study, the insulin level increased 3.6 μIU/ml (8.01
to 11.7 μIU/ml) in the zinc group. Although this increase was within
statistically significance, no improvement was observed in glycemic
control. The lack of improvement in insulin sensitivity following zinc
supplementation, despite an increase in circulating insulin, might be
due to the complex cellular mechanisms involved in insulin resistance.
Several factors including the response of insulin receptor, the function
of GLUT 4 especially in muscles and adipose tissue, disturbed fatty acids
metabolism, inflammation, gut microbial dysbiosis and the level of
other hormones [30,31] could have a determinant role, which were not
probably improved with zinc supplementation. A review article has
proposed that only trials with a significant number of patients with
subnormal zinc status showed improvements in glycemic control fol-
lowing supplementation [32]. More than 50% of patients in this study
had insufficient serum zinc status. Thus, the current study might be a
counterexample and indicates the presence of more potential compli-
cated determinants in zinc efficacy. The severity of metabolic dis-
turbances and duration of supplementation might also play a role. In
the current study, baseline HbA1c was more than 7.5 in 80%, and the
duration of diabetes was more than five years in 85% of the partici-
pants. A recent clinical trial showed the efficacy of supplementation
with 30mg daily zinc sulfate for six months in improving glycemic
control in patients with pre-diabetes [27] that had less metabolic
complications and disease duration. Differences in other co-morbidities
and protocol of medications in previous studies might also explain part
of discrepancies in findings of zinc trials [32].
Although several studies have investigated the role of zinc on glu-
cose and insulin homeostasis, little is known about the association be-
tween zinc function and adiponectin. Adiponectin production is in-
creased by PPAR agonists such as the anti-diabetic medications
thiazolidinediones [10]. Besides, it has been stated that zinc could
regulate PPARγ signaling [9]. The PPARγ expression and activation
reduced significantly in zinc deficiency and reversed with zinc sup-
plementation [33,34]. Thus, in this study, it was hypothesized that
improvement in zinc status following supplementation will lead to
higher PPARγ and adiponectin levels and consequently better glycemic
control. The findings have indicated considerable improvement in zinc
status and a simultaneous increase in adiponectin concentration within
the zinc group. However, this increase did not differ significantly from
the control group and seems to be clinically inadequate to improve
glycemic control. Different physiological concentrations of adiponectin
have been suggested. In general, values between 2-30 μg/ml could be
considered for normal population [35,36]. Comparing the values of
adiponectin in this study with other trials showed notable variations in
baseline values and changes following interventions, which restricts the
possibility to recognize the clinically important changes in adiponectin
concentration. Several variables including BMI, body fat percentage,
metabolic status, diet, and medications could affect adiponectin levels.
Besides, there is a heterogeneity in standards, laboratory techniques,
type of adiponectin, unit of measurement and methodologies in pre-
vious studies. We have previously reported the efficacy of bariatric
surgery [37] and nutritional supplements green tea extract [38] and
quercetin [39] in improving adiponectin concentration and glycemic
control in patients with insulin resistance. However, few clinical data
are available investigating the effect of zinc on adiponectin levels.
Twelve-week supplementation with 50mg/day zinc as zinc sulfate in
individuals with normal glucose tolerance test increased adiponectin
levels significantly compared to the control group [40].
Supplementation with 30mg/day zinc as zinc gluconate for 8 weeks in
young obese women improved serum zinc status within the interven-
tion group but did not affect insulin sensitivity or adiponectin con-
centration significantly [41]. Experimental studies in obesity-linked
type 2 diabetic mice [14] and high-fat diet-fed streptozotocin induced
diabetic rats [15] have reported an increase in adiponectin concentra-
tion and better glycemic control following 4-week oral administration
of 5-15mg/kg body weight zinc compounds. It has been shown that
different zinc compounds could exert distinctive effects on glycemic
control and adiponectin levels [42,43]. As adiponectin expression and
concentration decline in diabetes, zinc supplementation in the current
trial might just compensate for this decrease and probably different
doses and durations are required to observe consequent clinical effi-
cacy. Moreover, experimental models usually use active and highly
absorbable complexes of zinc that could affect the results.
The findings of the current trial indicated a significant increase in
HDL concentration, but not in TG, LDL, and total cholesterol, compared
to the control group. Other studies showed controversial results. No
significant changes were observed in lipid profile following three
months supplementation with 30mg/d zinc (as zinc sulfate) in patients
with diabetes [23]. Other studies showed an increase in HDL levels in
both patients supplemented with 100mg zinc sulfate for 12 weeks and
controls compared to baseline and a decrease in TG and cholesterol
levels within the zinc group. These changes were not significantly dif-
ferent between intervention and control groups at the end of the study
[18]. Besides, another trial in diabetes reported reductions in TG, TC,
and LDL levels, but not HDL values, within the zinc group receiving
660mg zinc sulfate for 6 weeks, which was not albeit different from the
controls at the end of the study [24]. It should be considered that our
patients did not have dyslipidemia, except for low HDL concentrations,
at baseline, which could impact the efficacy of the intervention. In
overall, despite significant improvement in HDL levels in the current
trial, more studies are required to confirm the beneficial effect of zinc
on lipid profiles and cardiovascular risk factors.
In the present study, there were no statistically significant changes
in weight, BMI, waist circumference and dietary reported intakes be-
tween the two groups during the study. Thus, the changes in anthro-
pometric measurements or dietary intakes could not be confounding
factors in the interpretation of the observed results.
Despite sufficient evidence provided by cellular and experimental
studies, many trials including the current study failed to show a re-
markable advantage for zinc supplementation in diabetes. Additionally,
many previous claimed positive results were interestingly limited to
post- vs. pre-values in the intervention groups and did not actually
differ significantly from controls. Thus, despite a long time in-
vestigating the role of zinc in glucose homeostasis, it seems premature
to recommend zinc supplementation to improve glycemic control in
diabetes.
There are some limitations to this study. Patients had a range of BMI
from normal weight to obese. The potential effect of BMI has been
considered in statistical analyses, however, investigating specific
groups of patients in the future will better clarify the findings.
Additionally, considering specific ranges of age, diabetes duration, and
HbA1c control in future studies might lead to recognition of subgroups
of diabetic patients that benefit from zinc supplementation.
5. Conclusion
The findings showed significant improvement in serum zinc status
following 12 weeks supplementation with zinc in patients with dia-
betes. Serum adiponectin concentrations increased significantly and
were probably partly restored compared to baseline in the intervention
group. Similarly, serum insulin levels increased significantly in the zinc
group; however, no improvement was observed in glycemic control at
the end of the study. Serum HDL levels, but not other lipid profiles,
improved considerably following supplementation. The findings of the
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current study did not support zinc supplementation to improve glucose
homeostasis in patients with diabetes.
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